



For Immediate Release

Contact: Tom Szczepanski, Director of Marketing

IVDiagnostics
219-801-1269
tom@ivdiagnostics.com

Valparaiso – IVDiagnostics was recently awarded \$244,479 in grants under the Qualifying Therapeutic Discovery Project program (QTDP).

IVDiagnostics was formed to develop, test and market more effective diagnostic tools for addressing rare circulating tumor cells.

“The IRS, in conjunction with the Department of Health and Human Services, approved applications for projects that showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness under the Qualifying Therapeutic Discovery Project program.”

Under the program, a total amount of \$1 billion was allocated for credits and grants with a \$5 million limit per each eligible applicant. The state of Indiana was awarded \$10,309,166 of the \$1 billion program.

IVDiagnostics is a biomedical diagnostic company focused on developing diagnostic tests for blood borne diseases. The project that qualified for this award was the IVDiagnostics biomedical platform, IVD Onco Dx.

This platform comprises technology that will assist physicians and oncologists with an efficient and highly accurate method for monitoring and diagnosing circulating tumor cells (CTCs). The IVD platform is novel as it utilizes an in vivo method for the diagnosis of 20-25% of blood in a patient’s circulatory system without drawing blood.

Frank Szczepanski, CEO of IVDiagnostics stated that "he was extremely pleased that the Company was recognized. This award validates IVDiagnostics' research and goal of providing physicians with more effective diagnostic tools and therefore helping save cancer patients' lives."

For further information please visit: www.ivdiagnostics.com